Cefiderocol is the first antibiotic with effluent flow rate–based dosing recommendations outlined in the product label for patients receiving continuous renal replacement therapy (CRRT). We aimed to investigate the population pharmacokinetics of cefiderocol among patients receiving CRRT and validate these dosing recommendations. A multicenter, prospective cefiderocol pharmacokinetic study among intensive care unit patients receiving CRRT was conducted (2022–2023). Blood sampling was performed at steady-state and cefiderocol concentrations were assayed by validated liquid chromatography–tandem mass spectrometry. Population pharmacokinetic analyses were conducted in Pmetrics using R software. The free time above the minimum inhibitory concentration (f T > MIC) and total daily area under the concentration time curve (AUCdaily) were calculated. Fourteen patients with effluent flow rates ranging from 2.1 to 5.1 L/h were enrolled. Cefiderocol concentrations best fitted a 2-compartment model. Mean ± standard deviation (SD) parameter estimates for clearance, central compartment volume, and intercompartment transfer constants (k12 and k21) were 3.5 ± 1.5 L/hour, 10.7 ± 8.4 L, 3.9 ± 1.8 hours−1, and 2.2 ± 2.2 hours−1, respectively. With simulations based on product label dosing recommendations, all patients achieved 100% fT > MIC up to MIC 8 mg/L with an AUCdaily (mean ± SD) of 1444 ± 423 mg × hour/L. Cefiderocol was well tolerated among the 14 patients. The current package insert dosing recommendations resulted in pharmacodynamically optimized cefiderocol exposures. Cefiderocol concentrations exceeded relevant MIC breakpoints in all patients at each effluent flow rate, and AUCdaily was within the range observed in patients in the phase 3 clinical trials, suggestive of a safe and therapeutic drug profile.
4 June 2025 in Antimicrobial Agents and Chemotherapy
Cefepime-taniborbactam dosing in patients undergoing continuous renal replacement therapy (CRRT) is unknown. We employed an ex vivo CRRT model to characterize transmembrane clearance (CL TM ) and derive optimal dosing regimens for patients supported by CRRT. CL TM was determined in CVVH and CVVHD modes using the Prismaflex ST150 and HF1400 hemofilter sets. Samples were collected over 60 minutes to determine cefepime and taniborbactam concentrations at increasing effluent flow rates (ER). Sieving (SC) and saturation (SA) coefficients were measured and used to calculate CL TM . Multiple linear regression determined cefepime and taniborbactam CL TM as a function of ER, hemofilter, and mode. An established population pharmacokinetic model was integrated with the CL TM , and a 1,000 patient Monte Carlo Simulation was conducted to determine exposures of potential dosing regimens for pneumonia. The overall mean ± SD SC/SA across CRRT modes, hemofilters, and ERs were 1.13 ± 0.08 and 1.03 ± 0.07 for cefepime and taniborbactam, respectively. ER was the primary driver ( P < 0.001) of CL TM for both drugs. For ER <3.5 L/h, cefepime and taniborbactam 1 g–0.25g q8h and 2 g–0.5g q12h as 4 h infusions achieved high probability of pharmacodynamic target attainment while keeping area under the curve exposures consistent with the proposed dose in pneumonia in non-CRRT patients. For ER ≥3.5 L/h, the optimum regimen was cefepime and taniborbactam 2 g–0.5 g q8h as a 4 h infusion. When incorporated into a population pharmacokinetic model, these CL TM data were used to propose dosing recommendations for cefepime and taniborbactam as a function of ER in patients undergoing CRRT.
15 May 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Background: Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex (CRAB) bacteremia and ventilator‐associated bacterial pneumonia (VABP). Methods: A 59‐year‐old critically ill patient (body mass index 60 kg/m 2 ) required CVVH and developed CRAB bacteremia secondary to VABP. Sulbactam‐durlobactam 2 g every 4 h infused over 3 h was initiated based on previous ex vivo data and the effluent rate of 6 L/h. The sulbactam‐durlobactam minimum inhibitory concentration (MIC) was determined by reference broth microdilution, and whole genome sequencing (WGS) was performed. Steady‐state pre‐filter blood, post‐filter blood, and effluent samples were collected on three different dosing intervals to characterize plasma exposure and estimate the sieving coefficient (SC). Results: The sulbactam‐durlobactam MIC was 4/4 mcg/mL (susceptible). WGS revealed penicillin‐binding protein (PBP)‐1b and PBP‐3 mutations. The selected dose exceeded sulbactam and durlobactam PK/pharmacodynamic (PD) targets with 100% free time above MIC ( f T > MIC) and the ratio of area under the unbound concentration‐time curve to MIC ( f AUC/MIC) = 139, respectively. The SC for sulbactam and durlobactam was 0.68 and 0.67, respectively, and protein binding was 54% and 51%, respectively. Sulbactam‐durlobactam monotherapy resulted in initial microbiological clearance for CRAB bacteremia but recurred later in hospitalization 11 days after sulbactam‐durlobactam treatment. The patient was ultimately transitioned to comfort care. Conclusion: Sulbactam‐durlobactam monotherapy dosed at 2 g every 4 h (3‐h infusion) in CVVH achieved PD targets for this CRAB isolate with a MIC of 4/4 mcg/ml. Although sulbactam‐durlobactam monotherapy resulted in initial microbiological clearance for the CRAB bacteremia, recurrence occurred, and the patient ultimately died.
There are increasing reports of carbapenem-resistant Enterobacterales (CRE) that test as cefepime-susceptible (S) or susceptible-dose dependent (SDD). However, there are no data to compare the cefepime testing performance of BD Phoenix automated susceptibility system (BD Phoenix) and disk diffusion (DD) relative to reference broth microdilution (BMD) against carbapenemase-producing (CP blaKPC -CRE) and non-producing (non-CP CRE) isolates. Cefepime susceptibility results were interpreted according to CLSI M100Ed32. Essential agreement (EA), categorical agreement (CA), minor errors (miEs), major errors (MEs), and very major errors (VMEs) were calculated for BD Phoenix (NMIC-306 Gram-negative panel) and DD relative to BMD. Correlates were also analyzed by the error rate-bounded method. EA and CA for CP blaKPC -CRE isolates ( n = 64) were <90% with BD Phoenix while among non-CP CRE isolates ( n = 58), EA and CA were 96.6%, and 79.3%, respectively. CA was 10% for CP blaKPC -CRE and non-CP CRE with BD Phoenix and DD tests. For error rate-bounded method, miEs were <40% for I High + 1 to I Low − 1 ranges for CP blaKPC -CRE and non-CP CRE with BD Phoenix. Regarding disk diffusion, miEs were unacceptable for all MIC ranges among CP blaKPC -CRE. For non-CP CRE isolates, only I High + 1 to I Low − 1 range was acceptable at 37.2%. Using this challenge set of genotypic-phenotypic discordant CRE, the BD Phoenix MICs and DD susceptibility results trended higher (toward SDD and resistant phenotypes) relative to reference BMD results yielding lower CA. These results were more prominent among CP blaKPC -CRE than non-CP CRE.
7 May 2025 in Antimicrobial Agents and Chemotherapy
Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates ( n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.
27 October 2025 in Journal of Antimicrobial Chemotherapy
Background: Stenotrophomonas maltophilia causes severe infections with limited treatment options. Aztreonam-avibactam demonstrates in vitro activity against this important pathogen with an MIC90 of 4/4 mg/L, but the efficacy of this agent is unknown. Herein, we used the neutropenic thigh infection model to assess in vivo efficacy against S. maltophilia. Methods: S. maltophilia isolates (n = 27) resistant to aztreonam (MIC ≥64 mg/L) and with aztreonam-avibactam MICs between 2/4 and >16/4 mg/L were examined using a neutropenic murine thigh infection model. Pharmacokinetic studies were performed for the development of a human-simulated regimen (HSR) of aztreonam-avibactam (1.5–0.5 g q6h, 3h infusion) to mimic the human free plasma exposure profile. Efficacy of the aztreonam-avibactam HSR was defined as ≥1 log10 cfu/thigh reduction at 24 h compared with baseline bacterial burden. Results: Among investigated isolates, the mean baseline bacterial burden in the model was 6.22 ± 0.16 log10 cfu/thigh. Without treatment, isolates grew on average to 7.81 ± 0.44 log10 cfu/thigh at 24 h. With aztreonam-avibactam HSR administration, 78% (7/9), 67% (6/9), 29% (2/7) and 0% (0/2) reached ≥1 log10 cfu/thigh reduction at MICs of 2/4, 4/4, 8/4 and ≥16/4 mg/L, respectively. Conclusions: Aztreonam-avibactam HSR demonstrated in vivo efficacy against the majority of S. maltophilia isolates with MIC ≤4/4 mg/L in a neutropenic murine thigh infection model. These results provide decision support to standards development organizations for determination of susceptibility breakpoints for aztreonam-avibactam against S. maltophilia.